Oncology Company Alpha Tauは、2900万ドルを調達
Founded in 2016 and headquartered within Tel Aviv University, Alpha Tau uses alpha radiation to treat various types of solid tumors.
Currently in clinical-stage, Alpha Tau’s technology targets cancer cells by inserting a seed containing Radium-224 atoms into the tumor. Radiation particles are then released when the radioactive substance decays inside the tumor, killing the surrounding cells. The firm has raised $29 million in a funding round led by Jerusalem-based late-stage investment firm Shavit Capital.
The latest investment brings Alpha Tau’s total funding raised to $54 million.